Dynamic Observation of Colonic Lesions, Commensal Microbiome, and Mycobiome Variations in Trinitrobenzene Sulfonic Acid-Induced Experimental Crohn’s Disease in Rats
Digestion · 2025
DOI: 10.1159/000543337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestion, 2025. Verfasst von Jingui Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Yangzhou University, Yangzhou, China, mjliu1@163.com. Hauptthemen laut MEDLINE: Crohn Disease, Gastrointestinal Microbiome, Colon, Mycobiome. Die Arbeit nennt 59 Literaturangaben.
Abstract (Originalsprache)
Introduction
Crohn’s disease (CD) is an inflammatory bowel disease characterized by chronic inflammation of the entire digestive lining. Although the pathogenesis of CD remains unclear, multiple factors, especially altered microbiota, are among its causes.
Methods
In this study, an experimental CD model was established by trinitrobenzene sulfonic acid (TNBS) enema. Then the dynamic changes of colonic tissue lesions, tight junctions, inflammation response, and oxidative stress are respectively tested by hematoxylin and eosin staining, immunofluorescence staining, and commercial kits. 16S rRNA and ITS sequencing of colonic feces were applied to analyze the composition and diversity of the microbiome and mycobiome for lasting 5 weeks.
Results
As a result, despite TNBS being applied only once time, the stimuli-caused injury reached a peak in the second week (the most severe period), after which symptoms began to gradually return to the normal stage. Additionally, consistent with the TNBS-caused colonic damage, deaths were also concentrated within 2 weeks after modeling, with only one death occurring in the subsequent period despite ongoing inflammation and other typical symptoms. In terms of gut bacteria, microbiome diversity decreased significantly while mycobiome diversity increased, along with the enrichment of harmful microbiota and shrinkage of probiotic microorganisms.
Conclusion
Therefore, the data suggested that TNBS-induced CD can be roughly divided into two phases: the acute inflammatory phase (weeks 1–2) and the chronic inflammatory phase (weeks 3–5). However, the microbiome and mycobiome dysbiosis did not return to normal within the trial period. Hence, our findings may facilitate a better comprehension of the dynamic progress of experimental TNBS-induced CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Veterinary Medicine, Yangzhou University, Yangzhou, China, mjliu1@163.com.
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China, mjliu1@163.com.
- Jiangsu Agri-Animal Husbandry Vocational College, Taizhou, China.
- College of Veterinary Medicine, Yangzhou University, Yangzhou, China.
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China.
- Shanghai JFKR Organoid Biotechnology Co., Ltd, Shanghai, China.
Zitieren
APA
Li, J., Liu, M., Wang, H., Huang, J., Huai, Y., Yu, C., Fang, G., Zhang, M., Bo, R., Fan, K., & Li, J. (2025). Dynamic Observation of Colonic Lesions, Commensal Microbiome, and Mycobiome Variations in Trinitrobenzene Sulfonic Acid-Induced Experimental Crohn’s Disease in Rats. Digestion. https://doi.org/10.1159/000543337
Vancouver
Li J, Liu M, Wang H, Huang J, Huai Y, Yu C, et al. Dynamic Observation of Colonic Lesions, Commensal Microbiome, and Mycobiome Variations in Trinitrobenzene Sulfonic Acid-Induced Experimental Crohn’s Disease in Rats. Digestion. 2025. doi:10.1159/000543337
BibTeX
@article{Li2025,
author = {Li, Jingui and Liu, Mingjiang and Wang, Huiwen and Huang, Junjie and Huai, Yuying and Yu, Chenglong and Fang, Guoqing and Zhang, Minxia and Bo, Ruonan and Fan, Kai and Li, Jingui},
title = {Dynamic Observation of Colonic Lesions, Commensal Microbiome, and Mycobiome Variations in Trinitrobenzene Sulfonic Acid-Induced Experimental Crohn’s Disease in Rats},
journal = {Digestion},
year = {2025},
doi = {10.1159/000543337}
}
EUVIMED